SAGA Diagnostics, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with Astra Zeneca to develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies. James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca, said: “We […]